Posted from: Monday, February 01, 2016 - 01:47 PM - Present

Xeomin Approved for Upper Limb Spasticity

December 29, 2015 – The U.S. Food and Drug Administration (FDA) approved Xeomin (incobotulinumtoxinA) in the treatment for upper limb spasticity (ULS) in adults and granted temporary approval for improving frown lines between the eyebrows (glabellar lines).  Xeomin had been originally approved in 2010 for treating muscle spasms associated with cervical dystonia (severe and painful neck muscle spasms) and blepharospasm (involuntary closing of the eyelids).  Xoemin is manufactured by Merz Pharma.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Friday, November 24, 2017 - 03:40 AM.